Esserman LJ - Search Results

1

Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Mukhtar RA, Yau C, Rosen M, Tandon VJ; I-SPY 1 TRIAL and ACRIN 6657 Investigators; Hylton N, Esserman LJ. Mukhtar RA, et al. Among authors: esserman lj. Ann Surg Oncol. 2013 Nov;20(12):3823-30. doi: 10.1245/s10434-013-3038-y. Epub 2013 Jun 19. Ann Surg Oncol. 2013. PMID: 23780381 Free PMC article. Clinical Trial.

2

Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.

Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ. Kuerer HM, et al. Among authors: esserman lj. Ann Surg Oncol. 2000 Jun;7(5):325-32. doi: 10.1007/s10434-000-0325-1. Ann Surg Oncol. 2000. PMID: 10864338

3

Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability.

Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Kinkel K, et al. Among authors: esserman lj. AJR Am J Roentgenol. 2000 Jul;175(1):35-43. doi: 10.2214/ajr.175.1.1750035. AJR Am J Roentgenol. 2000. PMID: 10882243

4

Integration of breast imaging into cancer management.

Esserman LJ, Wolverton D, Hylton N. Esserman LJ, et al. Curr Oncol Rep. 2000 Nov;2(6):572-81. doi: 10.1007/s11912-000-0112-y. Curr Oncol Rep. 2000. PMID: 11122895 Review.

5

Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Esserman L, Hylton N, George T, Weidner N. Esserman L, et al. Breast J. 1999 Jan;5(1):13-21. doi: 10.1046/j.1524-4741.1999.005001013.x. Breast J. 1999. PMID: 11348250

6

Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma.

Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H. Foster RD, et al. Among authors: esserman lj. Ann Surg Oncol. 2002 Jun;9(5):462-6. doi: 10.1007/BF02557269. Ann Surg Oncol. 2002. PMID: 12052757

7

Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy.

Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Partridge SC, et al. Among authors: esserman lj. AJR Am J Roentgenol. 2002 Nov;179(5):1193-9. doi: 10.2214/ajr.179.5.1791193. AJR Am J Roentgenol. 2002. PMID: 12388497

8

Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity.

Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Hwang ES, et al. Among authors: esserman lj. Ann Surg Oncol. 2003 May;10(4):381-8. doi: 10.1245/aso.2003.03.085. Ann Surg Oncol. 2003. PMID: 12734086

9

Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy.

Esserman L. Esserman L. Ann Surg Oncol. 2004 Jan;11(1 Suppl):3S-8S. doi: 10.1007/BF02524789. Ann Surg Oncol. 2004. PMID: 15015703 Review. No abstract available.

10

Applying the neoadjuvant paradigm to ductal carcinoma in situ.

Esserman L, Sepucha K, Ozanne E, Hwang ES. Esserman L, et al. Ann Surg Oncol. 2004 Jan;11(1 Suppl):28S-36S. doi: 10.1007/BF02524793. Ann Surg Oncol. 2004. PMID: 15015707

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

442 results

Search Page

Filters